Quazar Investment completed a $50m investment in NuroMENA Holdings.

Quazar Investment, a private investment firm based in Dubai, United Arab Emirates, completed a $50m investment in NuroMENA Holdings, a UAE-based subsidiary of NeOnc Technologies, a Nasdaq-listed biotechnology company pioneering therapies for central nervous system (CNS) cancers. "We view this as a defining moment for NeOnc and a major validation of our global vision. With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped ot continue our goals toward delivering life-saving therapies to a region in urgent need of innovation. This partnership not only brings capital it brings conviction, commitment, and alignment on purpose," Amir Heshmatpour, NeOnc Executive Chairman and President.